Abstract Details Title Rimegepant 75 mg is Effective for the Acute Treatment of Migraine Regardless of Attack Frequency: Results From 3 Phase 3 Trials Topic Headache Presentation(s) P6 - Poster Session 6 (12:00 PM-1:00 PM) Poster/Presentation Number 7-005 Objective The objective of this study was to evaluate the influence of migraine attack frequency on the efficacy of rimegepant. Background Acute treatment is used by almost everyone with migraine, regardless of attack frequency. Rimegepant is a small molecule CGRP receptor antagonist with demonstrated efficacy and safety in the acute treatment of migraine.